Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex

Journal of Neurochemistry

Volumn 107, Issue 4, 2008, Pages 941-951

  Pillai, Anilkumar ^a,b   Veeranan Karmegam, Rajalakshmi ^a,b   Dhandapani, Krishnan M ^a   Mahadik, Sahebarao P ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Cystamine; Cysteamine; Haloperidol; Neuroprotection; Schizophrenia

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYSTAMINE; GLUTATHIONE; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN PROTECTION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; FETUS; FRONTAL CORTEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CELLS, CULTURED; CYSTAMINE; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRONTAL LOBE; GENE EXPRESSION REGULATION; GLUTATHIONE; HALOPERIDOL; MALE; MICE; NEURONS; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; TIME FACTORS;

MUS; RATTUS; RODENTIA;

EID: 54349112440     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05665.x     Document Type: Article

References (57)

1. Alleva E., Della Seta D., Cirulli F. Aloe L. (1996) Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 483 489.
2. Altar C. A., Cai N., Bliven T., Juhasz M., Conner J. M., Acheson A. L., Lindsay R. M. Wiegand S. J. (1997) Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856 860.
3. Angelucci F., Aloe L., Gruber S. H., Fiore M. Mathe A. A. (2000) Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int. J. Neuropsychopharmacol. 3, 13 25.
4. Arnold S. E., Talbot K. Hahn C. G. (2005) Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog. Brain Res. 147, 319 345.
5. Baldessarini R. J., Cohen B. M. Teicher M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45, 79 91.
6. Bartrup J. T., Moorman J. M. Newberry N. R. (1997) BDNF enhances neuronal growth and synaptic activity in hippocampal cell cultures. Neuroreport 8, 3791 3794.
7. Ben-Shachar D. Laifenfeld D. (2004) Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59, 273 296.
8. Berton O., McClung C. A., Dileone R. J. et al. (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864 868.
9. Borrell-Pages M., Canals J. M., Cordelieres F. P. et al. (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410 1424.
10. Buckley P. F., Mahadik S. P., Pillai A. Terry V. Jr. (2007) Neurotrophins and schizophrenia. Schizophr. Res. 94, 1 11.
11. Buttke T. M. Sandstrom P. A. (1994) Oxidative stress as a mediator of apoptosis. Immunol. Today 15, 7 10.
12. Bymaster F. P., Hemrick-Luecke S. K., Perry K. W. Fuller R. W. (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, a1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.) 124, 87 94.
13. Cabungcal J. H., Nicolas D., Kraftsik R., Cuenod M., Do K. Q. Hornung J. P. (2006) Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol. Dis. 22, 624 637.
14. Dardik R. Inbal A. (2006) Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp. Cell Res. 312, 2973 2982.
15. Dawson N. M., Hamid E. H., Egan M. F. Meredith G. E. (2001) Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 39, 70 81.
16. Dedeoglu A., Kubilus J. K., Jeitner T. M. et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942 8950.
17. Dhandapani K. M., Hadman M., De Sevilla L., Wade M. F., Mahesh V. B. Brann D. W. (2003) Astrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. J. Biol. Chem. 278, 43329 43339.
18. Didriksen M. (1995) Effects of antipsychotics on cognitive behavior in rats using the delayed non-match to position paradigm. Eur. J. Pharmacol. 28, 241 250.
19. Dudek H., Datta S. R., Franke T. F., Birnbaum M. J., Yao R., Cooper G. M., Segal R. A., Kaplan D. R. Greenberg M. E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661 665.
20. Eastwood S. L. (2004) The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int. Rev. Neurobiol. 59, 47 72.
21. Feifel D. Minor K. L. (1997) Cysteamine blocks amphetamine-induced deficits in sensorimotor gating. Pharmacol. Biochem. Behav. 58, 689 693.
22. Fox J. H., Barber D. S., Singh B. et al. (2004) Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413 422.
23. Haynes L. E., Barber D. Mitchell I. J. (2004) Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res. 1026, 157 167.
24. Huang E. J. Reichardt L. F. (2003) Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609 642.
25. Kang H. Schuman E. M. (1995) Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 267, 1658 1662.
26. Kaplan D. R. Miller F. D. (2000) Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurobiol. 10, 381 391.
27. Karpuj M. V., Becher M. W., Springer J. E., Chabas D., Youssef S., Pedotti R., Mitchell D. Steinman L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143 149.
28. Lang U. E., Jockers-Scherubl M. C. Hellweg R. (2004) State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J. Neural. Transm. 111, 387 411.
29. Lee F. S., Rajagopal R., Kim A. H., Chang P. C. Chao M. V. (2002) Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides. J. Biol. Chem. 277, 9096 9102.
30. Lesort M., Lee M., Tucholski J. Johnson G. V. (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 278, 3825 3830.
31. Lieberman J. A., Perkins D. O. Jarskog L. F. (2007) Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr. 12, 1 13.
32. Mahadik S. P., Pillai A., Joshi S. Foster A. (2006) Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int. Rev. Psychiatry 18, 119 131.
33. Molteni R., Calabrese F., Bedogni F., Tongiorgi E., Fumagalli F., Racagni G. Riva M. A. (2006) Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int. J. Neuropsychopharmacol. 9, 307 317.
34. Mufson E. J., Kroin J. S., Sobreviela T., Burke M. A., Kordower J. H., Penn R. D. Miller J. A. (1994) Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat. Exp. Neurol. 129, 15 26.
35. Niwa M., Hara A., Iwai T., Wang S., Hotta K., Mori H. Uematsu T. (2001) Caspase activation as an apoptotic evidence in the gerbil hippocampal CA1 pyramidal cells following transient forebrain ischemia. Neurosci. Lett. 300, 103 106.
36. Oliverio S., Amendola A., Rodolfo C., Spinedi A. Piacentini M. (1999) Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis. J. Biol. Chem. 274, 34123 34128.
37. Pang L., Sawada T., Decker S. J. Saltiel A. R. (1995) Inhibition of MAP kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270, 13585 13588.
38. Pillai A. (2008) Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals 16, 183 193.
39. Pillai A., Terry V., Jr. Mahadik S. P. (2006) Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 82, 95 106.
40. Pillai A., Parikh V., Terry V., Jr. Mahadik S. P. (2007) Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 41, 372 386.
41. Pillai A., Dhandapani K. M., Pillai B. A., Terry V., Jr. Mahadik S. P. (2008). Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology 33, 1942 1951.
42. Pinto J. T., Van Raamsdonk J. M., Leavitt B. R., Hayden M. R., Jeitner T. M., Thaler H. T., Krasnikov B. F. Cooper A. J. (2005) Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J. Neurochem. 94, 1087 1101.
43. Saarelainen T., Hendolin P., Lucas G. et al. (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23, 349 357.
44. Schinder A. F., Berninger B. Poo M. (2000) Postsynaptic target specificity of neurotrophin-induced presynaptic potentiation. Neuron 25, 151 163.
45. Skaper S. D., Floreani M., Negro A., Facci L. Giusti P. (1998) Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J. Neurochem. 70, 1859 1868.
46. Skarsfeldt T. (1996) Differential effect of antipsychotics on place navigation of rats in Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl.) 124, 126 133.
47. Slater A. F., Nobel C. S. Orrenius S. (1995) The role of intracellular oxidants in apoptosis. Biochim. Biophys. Acta 1271, 59 62.
48. Spina M. B. Cohen G. (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc. Natl Acad. Sci. USA 86, 1398 1400.
49. Swartz M. S., Perkins D. O., Stroup T. S. et al. CATIE Investigators (2007). Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 164 : 428 436.
50. Terry V., Jr. Mahadik S. P. (2007) Time dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J. Pharmacol. Exp. Ther. 320, 961 968.
51. Terry A. V., Parikh V., Nasrallah H. A. Mahadik S. P. (2004) Time dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons and spatial learning in rats. Biol. Psychiatry 55, 47S.
52. Terry V., Jr., Gearhart D. A., Warner S. E., Zhang G., Bartlett M. G., Middlemore M. L., Beck W. D., Jr., Mahadik S. P. Waller J. L. (2007) Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 146, 1316 1332.
53. Thoenen H. (1995) Neurotrophins and neuronal plasticity. Science 270, 593 598.
54. Tremblay M. E., Saint-Pierre M., Bourhis E., Levesque D., Rouillard C. Cicchetti F. (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol. Aging 27, 862 870.
55. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M. Brownell A. L. (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 231, 57 66.
56. Yan Q., Rosenfeld R. D., Matheson C. R., Hawkins N., Lopez O. T., Bennett L. Welcher A. A. (1997) Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 78, 431 448.
57. Yao J. K., Leonard S. Reddy R. (2006) Altered glutathione redox state in schizophrenia. Dis. Markers 22, 83 93.